Spinraza denied as not medically necessary by Aetna?

Aetna's specific coverage criteria for spinraza are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny Spinraza for Medical Necessity

A medical-necessity denial for Spinraza (nusinersen) from Aetna typically means the plan's reviewer determined that the submitted documentation did not sufficiently establish that the treatment is clinically required for this particular patient at this time. This is almost always a documentation problem, not a clinical one — the medical need is real, but the prior authorization submission did not present it in the structured format Aetna's reviewers require.

Medical-necessity denials for SMA therapies are highly appealable when the appeal is built around Aetna's own policy criteria, answered with specific chart evidence.

## Federal Appeal Rights

• ACA §2719 external review: Non-grandfathered plans must offer IRO review. You generally have approximately four months from the denial notice. External reviewers apply an independent clinical standard and are not bound by Aetna's internal determination.
• ERISA §503 full-and-fair review: Employer-plan members are entitled to see every piece of evidence and every criterion Aetna used — request it in writing immediately upon denial.
• Expedited review: Given that SMA is a progressive neuromuscular condition where delays in therapy can result in irreversible motor decline, an expedited appeal is often justified. Request it explicitly, citing the urgency.

## Documentation to Gather

• Confirmed SMA diagnosis: Genetic testing confirming SMN1 mutation and SMN2 copy number; neuromuscular specialist's diagnosis notes with ICD code.
• Functional status at baseline: Standardized motor function assessments documented in the chart; documentation of respiratory status, nutritional status, and independent function.
• Clinical trajectory: Serial office notes or assessments showing disease course — whether stable, improving, or declining — and the projected trajectory without intervention.
• Prior treatment history: Any prior SMA-directed therapies, supportive care, respiratory or nutritional interventions, with dates and outcomes.
• Prescriber medical-necessity letter: A letter from the treating neuromuscular specialist that addresses Aetna's specific medical-necessity criteria one by one, mapping each to a concrete chart finding. Generic letters are insufficient; the letter must be policy-specific.
• FDA prescribing information: Attach the current FDA-approved label confirming the approved indication.

## Criteria-Mapping Framework

Obtain Aetna's current Clinical Policy Bulletin for Spinraza. Build a response that mirrors its structure:

| Aetna Medical-Necessity Criterion | Evidence Submitted | |---|---| | Diagnosis confirmed by genetic testing | Genetic report, [date], [lab] | | Functional classification documented | Motor assessment, [date], documented in [note] | | Treatment goals and expected benefit stated | Specialist letter, [date] | | [Any other stated criterion] | [Specific chart citation] |

The appeal cover letter should open by stating that each of Aetna's criteria is met, then provide the table above, then attach the supporting documents in the order they are cited. This structure makes it easy for the reviewer to approve — which is the goal.